Pharsight

Drugs that contain Tenapanor Hydrochloride

1. Ibsrela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969377 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(5 years from now)

US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Aug, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408840 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder
Dec, 2029

(5 years from now)

US9006281 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
May, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 12, 2024

NCE-1 date: 2023-09-13

Market Authorisation Date: 12 September, 2019

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

More Information on Dosage

IBSRELA family patents

Family Patents

2. Xphozah patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8969377 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Dec, 2029

(5 years from now)

US8541448 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
Aug, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10272079 ARDELYX INC NHE3-binding compounds and methods for inhibiting phosphate transport
Apr, 2034

(10 years from now)

US10940146 ARDELYX INC NHE3-binding compounds and methods for inhibiting phosphate transport
Apr, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Oct 17, 2026
New Chemical Entity Exclusivity (NCE) Sep 12, 2024

NCE-1 date: 2023-09-13

Market Authorisation Date: 17 October, 2023

Treatment: Treatment of hyperphosphatemia; Reduction of serum phosphorus in adults

Dosage: TABLET;ORAL

More Information on Dosage

XPHOZAH family patents

Family Patents